Biotricity Q2 Revenue Climbs 11.5% as Gross Margin Widens to 83.3%
BTCY is trading near its 52-week low of $0.041 (10% above the low).
Summary
Biotricity posted fiscal Q2 revenue of $4.33 million, up 11.5% year over year, with gross margin widening to 83.3% from 81.9%. The growth came mostly from a 13.3% increase in technology fee revenue, the recurring piece of the business, and income from operations rose 23.7% even as operating expenses climbed 12.5%. R&D spending jumped 46.7%, the main driver of the expense increase. The margin expansion and operating leverage matter for a micro-cap that carried a going concern warning and a $31.7 million working capital deficit in its last 10-Q; sustained positive operating cash flow is the metric that determines whether that warning clears. This follows the September 25 8-K disclosing director Jainal Bhuiyan's resignation from the board and compensation committee.
At the time of this announcement, BTCY was trading at $0.05 on OTC in the Life Sciences sector, with a market capitalization of approximately $980.6K. The 52-week trading range was $0.04 to $0.59. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.